Drugs / LY4175408
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07046923 | Jul 2025 → Jul 2030 expected | endometrium neoplasm, metastatic neoplasm, non-small cell lung carcinoma, small cell lung carcinoma +1 | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4175408 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07046923 ↗ |
| Modality | Other / unclassified | “an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells” NCT07046923 ↗ |
| Route | Intravenous | “IV infusion” NCT07046923 ↗ |